Wire · opportunities
Peptide boom has states scrambling to protect consumers, Post investigation finds
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
A Washington Post investigation reveals significant regulatory gaps in the US peptide market, with medspas selling unstudied compounds with minimal oversight compared to restaurants or salons. The FDA and state boards are struggling to keep pace as peptides proliferate in gray and black markets.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building a peptide supply, verification or compliance platform, you're now selling into a market where your customer base has zero regulatory requirement to use you—and states are about to change that. Get ahead of the state-by-state crackdown with a product that helps medspas go compliant before enforcement arrives.
◆ Coverage
1 source · 24 Jul 2026
◆ Related on Wire
◆ Topics